Fundz

Cell Source, Inc. reported raising $8.88 Million in an initial SEC Form D filing, from an offering of $10 Million

PUBLIC · CLCSOct 18, 2019$8.9M of $10M raised

Amount Raised

$8.88 Million

$8.88 Million sold, per SEC Form D (first sale Oct 18, 2019)

Round Type

Venture

New YorkOtherBiotechnology

Quick answer

Cell Source, Inc. raised $8.88 Million in a funding round, dated October 18, 2019. Cell Source, Inc. is based in New York, New York, United States.

How much did Cell Source, Inc. raise?
Cell Source, Inc. raised $8.88 Million in a funding round on October 18, 2019.
What does Cell Source, Inc. do?
Cell Source focuses on developing cell therapy treatments based on the management of immune tolerance.
Where is Cell Source, Inc. based and how big is it?
Cell Source, Inc. is based in New York, New York, United States.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Cell Source, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Elixirgen Therapeutics raised $5.7M on December 2, 2019.
  • ReNetX Bio, Inc. raised $1.3M (Seed) on December 2, 2019.
  • Remedy Plan raised $5.2M on December 2, 2019.
  • Clarapath raised $36M on December 2, 2019.
  • Amyris raised $7.8M on November 29, 2019.
  • PROGENITY, INC. raised $31M on November 27, 2019.

Who to call at Cell Source, Inc., and when

A new round usually means Cell Source, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Cell Source, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cell Source, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cell Source, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cell Source, Inc.

Location

57 WEST 57TH STREET, SUITE 400

New York, New York, United States

About

Cell Source focuses on developing cell therapy treatments based on the management of immune tolerance.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cell Source, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Cell Source, Inc.'s next move

See what Strategic adds

Cell Source, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.